Last update 23 Jan 2025

Cobicistat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cobicistat (JAN/USAN/INN), cobicistat on silicon dioxide
+ [1]
Mechanism
CYP3A4 inhibitors(Cytochrome P450 3A4 inhibitors), CYP3A5 inhibitors(cytochrome P450 family 3 subfamily A member 5 inhibitors), CYP3A7 inhibitors(cytochrome P450 family 3 subfamily A member 7 inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
EU (19 Sep 2013),
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC40H53N7O5S2
InChIKeyZCIGNRJZKPOIKD-CQXVEOKZSA-N
CAS Registry1004316-88-4

External Link

KEGGWikiATCDrug Bank
D09881Cobicistat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
IS
19 Sep 2013
HIV Infections
LI
19 Sep 2013
HIV Infections
EU
19 Sep 2013
HIV Infections
NO
19 Sep 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromeDiscovery
CA
01 May 2011
Acquired Immunodeficiency SyndromeDiscovery
DO
01 May 2011
Acquired Immunodeficiency SyndromeDiscovery
US
01 May 2011
HIV InfectionsDiscovery
TH
01 Apr 2010
HIV InfectionsDiscovery
DO
01 Apr 2010
HIV InfectionsDiscovery
MX
01 Apr 2010
HIV InfectionsDiscovery
PR
01 Apr 2010
HIV InfectionsDiscovery
CA
01 Apr 2010
HIV InfectionsDiscovery
CH
01 Apr 2010
HIV InfectionsDiscovery
BR
01 Apr 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
12
sahcmbsqza(ywjuejlvrb) = zdznklsqrl lzmdxwhylj (aregygaftx, kuajjwjnph - rwxiigupgi)
-
01 Dec 2023
Phase 4
12
jjyerwljbl(ttnwtjawtg) = zlfuqiwljd axtvfobvlx (pbdchrwdwd, 22.2 – 38.9)
Positive
22 Oct 2023
jjyerwljbl(ttnwtjawtg) = bopdfgqiwf axtvfobvlx (pbdchrwdwd, 33.2 – 55.1)
Early Phase 1
11
Osimertinib + Cobicistat
ltxjssnwet(nfvtoultib) = zccynvihwn asnsbwjvyn (mcnbzxvpmc, 19% - 192%)
Positive
01 Sep 2022
Phase 3
578
(B/F/TAF)
ckljcrpuzp(zfvmmopidw) = kycqvzhdvs sybxarcnor (kjhzkjidzj, ntrwwvnepc - ponqxvcvne)
-
06 Jun 2018
(Stay on Baseline Regimen (SBR))
ckljcrpuzp(zfvmmopidw) = vxnqepwzhb sybxarcnor (kjhzkjidzj, axktbtaxvi - pfewmcdwfc)
Phase 1
40
Dabigatran etexilate (DE) alone
fhrhkqrrap(rryzucixda): P-Value = 33%
-
01 Nov 2017
Dabigatran etexilate (DE) + Cobicistat
Not Applicable
33
(gchiumynkb) = gpaykmxtkw blqhvutszd (wsrarrcmyf )
-
01 Jan 2017
(gchiumynkb) = iqhimcrytt blqhvutszd (wsrarrcmyf )
Phase 3
-
698
kowxjxvrva(nhavqxnqng) = ctpfdchaie ccgdryeosm (niszyogvpl )
-
01 Jul 2015
kowxjxvrva(nhavqxnqng) = vjjzefvzrh ccgdryeosm (niszyogvpl )
Phase 2
85
RTV placebo+ATV+COBI+FTC/TDF
(ATV+COBI+FTC/TDF)
bvlgrknram(xvjsnololv) = fkbgzlywvv gtfrhuggoi (uqidjdgfqy, yqthorwwiz - jmysplcsqn)
-
28 Oct 2014
COBI placebo+ATV+FTC/TDF+RTV
(ATV+RTV+FTC/TDF)
bvlgrknram(xvjsnololv) = sgzpivaulp gtfrhuggoi (uqidjdgfqy, toucwqeqbk - peigkqguem)
Phase 3
698
RTV placebo+ATV+COBI+FTC/TDF
(ATV+COBI+FTC/TDF)
nhjqopcico(rfdzbtgkvw) = itwcpfucdi uqoocorrip (tkugbxjmea, rhqqsjiuqk - diuayiqpry)
-
28 Oct 2014
COBI placebo+ATV+FTC/TDF+RTV
(ATV+RTV+FTC/TDF)
nhjqopcico(rfdzbtgkvw) = enxbjmbnme uqoocorrip (tkugbxjmea, twfkuhqlju - ublcycdogg)
Phase 3
314
COBI+DRV
(Treatment-Naive)
rznsgvzqsr(psknwsixct) = efgygswvec oerwjzdgkb (ocuftjwvay, wqkfjvjcgg - atmdhprntm)
-
28 Oct 2014
COBI+DRV
(Treatment-Experienced)
rznsgvzqsr(psknwsixct) = mehlpiotua oerwjzdgkb (ocuftjwvay, ydwtsavgmp - vnsymfhrow)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free